AtriCure (ATRC) vs Sanara MedTech (SMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AtriCure (ATRC) has outperformed Sanara MedTech (SMTI) over the past year, gaining 53.0% versus a gain of 10.9%. Over five years, SMTI leads with a +6.3% price change compared with -21.8% for ATRC. AtriCure is the larger company by market cap ($2.84 billion vs $322.2 million), about 8.8 times the size.
On valuation, Sanara MedTech trades at a lower forward P/E (64.9x vs 128.6x for AtriCure).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | SMTI |
|---|---|---|
| Share price | $55.81 | $35.07 |
| Market cap | $2.84B | $322.22M |
| 1-day change | +5.62% | +0.06% |
| YTD return | +41.08% | +50.19% |
| 1-year return | +53.03% | +10.95% |
| 5-year return | -21.80% | +6.34% |
| P/E ratio (TTM) | 265.76 | — |
| Forward P/E | 128.60 | 64.94 |
| EPS (TTM) | $0.21 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $534.53M | — |
| Revenue growth (YoY) | +14.88% | — |
| Net income (latest FY) | $-11.45M | — |
| Gross margin | 74.98% | — |
| Operating margin | -1.77% | — |
| Net margin | -2.14% | — |
| 52-week high | $61.70 | $35.34 |
| 52-week low | $25.36 | $16.05 |
| Distance from 52-week high | -9.55% | -0.76% |
| Analyst consensus | buy | none |
| Avg. price target upside | -1.65% | -0.20% |
| Average volume | 1.09M | 280.40K |
| Shares outstanding | 50.87M | 9.19M |
| Employees | 1,350 | 108 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AtriCure is about 8.8 times larger than Sanara MedTech by market value ($2.84B vs $322.22M).
- ATRC has outperformed SMTI by 42.1 percentage points over the past year.
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About Sanara MedTech
SMTI stock →Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
Health Care · Industrial Specialties · 108 employees
ATRC vs SMTI FAQ
Which is bigger, AtriCure or Sanara MedTech?
AtriCure (ATRC) is larger, with a market capitalization of $2.84B compared with $322.22M for Sanara MedTech (SMTI).
Which stock has performed better over the past year, ATRC or SMTI?
ATRC returned +53.03% over the past 12 months, compared with +10.95% for SMTI (price return, excluding dividends). Past performance does not predict future results.
Are AtriCure and Sanara MedTech in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for AtriCure and Industrial Specialties for Sanara MedTech.